NexImmune (NASDAQ:NEXI) Releases Earnings Results, Beats Expectations By $0.04 EPS

NexImmune (NASDAQ:NEXIGet Rating) announced its earnings results on Thursday. The company reported ($0.66) earnings per share for the quarter, topping the consensus estimate of ($0.70) by $0.04, MarketWatch Earnings reports.

Shares of NASDAQ NEXI traded down $0.01 on Friday, reaching $2.01. 331,685 shares of the company traded hands, compared to its average volume of 155,070. NexImmune has a fifty-two week low of $1.72 and a fifty-two week high of $19.50. The company has a 50 day moving average of $2.84 and a 200 day moving average of $4.56.

A number of analysts have weighed in on the stock. Barclays raised their price objective on shares of NexImmune from $4.00 to $7.00 and gave the stock an “overweight” rating in a report on Friday, April 1st. Raymond James lowered their price objective on shares of NexImmune from $21.00 to $13.00 and set an “outperform” rating on the stock in a research report on Tuesday, February 22nd. Zacks Investment Research upgraded shares of NexImmune from a “hold” rating to a “buy” rating and set a $2.75 target price on the stock in a research report on Thursday, February 24th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of NexImmune in a research report on Friday, April 1st.

In other NexImmune news, Director Sol J. Barer bought 30,000 shares of NexImmune stock in a transaction dated Friday, March 18th. The stock was bought at an average cost of $2.11 per share, for a total transaction of $63,300.00. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Kristi Jones bought 10,000 shares of NexImmune stock in a transaction dated Tuesday, March 29th. The shares were acquired at an average price of $3.74 per share, with a total value of $37,400.00. The disclosure for this purchase can be found here. Insiders have bought a total of 128,978 shares of company stock valued at $378,359 in the last quarter. Company insiders own 18.50% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of NEXI. Morgan Stanley acquired a new stake in shares of NexImmune in the first quarter valued at $493,000. PNC Financial Services Group Inc. raised its position in shares of NexImmune by 566.8% in the first quarter. PNC Financial Services Group Inc. now owns 111,882 shares of the company’s stock valued at $471,000 after purchasing an additional 95,104 shares during the period. Renaissance Technologies LLC raised its position in shares of NexImmune by 44.7% in the first quarter. Renaissance Technologies LLC now owns 73,661 shares of the company’s stock valued at $310,000 after purchasing an additional 22,761 shares during the period. American International Group Inc. raised its position in shares of NexImmune by 155.1% in the third quarter. American International Group Inc. now owns 9,662 shares of the company’s stock valued at $146,000 after purchasing an additional 5,875 shares during the period. Finally, Wells Fargo & Company MN raised its position in shares of NexImmune by 266.4% in the second quarter. Wells Fargo & Company MN now owns 7,343 shares of the company’s stock valued at $120,000 after purchasing an additional 5,339 shares during the period. Institutional investors and hedge funds own 58.40% of the company’s stock.

About NexImmune (Get Rating)

NexImmune, Inc, a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform.

Read More

Earnings History for NexImmune (NASDAQ:NEXI)

Receive News & Ratings for NexImmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NexImmune and related companies with MarketBeat.com's FREE daily email newsletter.